Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith P Mitchell

Showing results (41-50 of 86) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Cancer Biology & Therapy|May 1, 2010
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancersAgnieszka K Witkiewicz, Abhijit Dasgupta, Sara Sammons, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 28, 2011
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinomaTimothy N Showalter, Tingting Zhan, P Rani Anne, et al.
Cancer|January 6, 2017
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancerBrandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, et al.
Cancer Biology & Therapy|May 8, 2020
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancersOlena Odnokoz, Pengfei Yu, Amy R Peck, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 6, 2020
Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer DatabaseSamantha L Savitch, Tyler R Grenda, Walter Scott, et al.
Cancers|June 10, 2023
Physician Perceptions on Cancer Screening for LGBTQ+ PatientsNicolas G Nelson, Joseph F Lombardo, Ayako Shimada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal CancerAparna R Parikh, Fa-Chyi Lee, Linda Yau, et al.
Pageof 9

Showing results (41-50 of 86) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancerRamesh K Ramanathan, Jeffery W Clark, Nancy E Kemeny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2023
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Bruce J Giantonio, Paul J Catalano, Neal J Meropol, et al.
Cancer Biology & Therapy|May 1, 2010
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancersAgnieszka K Witkiewicz, Abhijit Dasgupta, Sara Sammons, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 28, 2011
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinomaTimothy N Showalter, Tingting Zhan, P Rani Anne, et al.
Cancer|January 6, 2017
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancerBrandon Bernard, Vinayak Muralidhar, Yu-Hui Chen, et al.
Cancer Biology & Therapy|May 8, 2020
Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancersOlena Odnokoz, Pengfei Yu, Amy R Peck, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|June 6, 2020
Racial Disparities in Rates of Surgery for Esophageal Cancer: a Study from the National Cancer DatabaseSamantha L Savitch, Tyler R Grenda, Walter Scott, et al.
Cancers|June 10, 2023
Physician Perceptions on Cancer Screening for LGBTQ+ PatientsNicolas G Nelson, Joseph F Lombardo, Ayako Shimada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal CancerAparna R Parikh, Fa-Chyi Lee, Linda Yau, et al.
Pageof 9